Novartis and Spark Therapeutics have entered a licensing agreement, with Novartis obtaining the rights to develop, register and commercialize Luxturna outside of the United States, according to a press release.
Luxturna (voretigene neparvovec-rzyl) is the first gene therapy approved to restore vision in patients with biallelic mutations of the RPE65 gene.
Novartis will make an upfront cash payment of $105 million to Spark, as well as milestone payments up to $65 million, according to a press release from Spark. Spark will remain responsible for obtaining approval from the European Medicines
Uncategorized